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Abstract
Background: Panaxatriol saponins (PTS), an extract from the traditional Chinese herb Panax notoginseng, which
has been used to treat ischemic stroke for many years in China. However, the mechanism underlying the effects
of PTS remains unclear. This study aimed to determine whether PTS can protect against ischemic brain injury by
promoting angiogenesis and to explore the possible mechanism by which it promotes angiogenesis.
Methods: Middle cerebral artery occlusion (MCAO) was induced in rats, and neurological deficit scores and
brain infarct volumes were assessed. Micro-Positron emission tomography (PET) was adopted to assess cerebral
perfusion, and real-time PCR and western blotting were used to evaluate vascular growth factor and Sonic
hedgehog (Shh) pathway component levels. Immunofluorescence staining was used to determine capillary
densities in ischemic penumbrae.
Results: We showed that PTS improved neurological function and reduced infarct volumes in MCAO rats. Micro-
PET indicated that PTS can significantly increase 18F-fluorodeoxyglucose (18F-PDG) uptake by ischemic brain tissue
and enhance cerebral perfusion after MCAO surgery. Moreover, PTS was able to increase capillary densities and
enhance angiogenesis in ischemic boundary zones and up-regulate vascular endothelial growth factor (VEGF) and
Angiopoietin-1 (Ang-1) expression by activating the Shh signaling pathway.
Conclusion: These findings indicate that PTS exerts protective effects against cerebral ischemic injury by
enhancing angiogenesis and improving microperfusion.
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Background
Stroke is the second-most fatal disease worldwide [1],
and ischemic stroke is the most common cause of stroke
[2]. Restoring cerebral blood flow and saving dying
neurons are considered effective therapies for ischemic
brain injury. Thrombolytic therapy with recombinant
tissue plasminogen activator (rt-PA) is approved by the
FDA for treating acute cerebral infarctions [3], but the
majority of patients can not benefit from it due to its
narrow treatment time window and association with
hemorrhagic complications. Therefore, new therapies
must be developed to treat the large numbers of patients
suffering from ischemic brain injury. Angiogenesis, the
formation of new blood vessels from preexisting vessels
[4], can improve tissue microperfusion in ischemic
boundary regions. A previous study showed that patients
with higher penumbra vascular densities can survive for
longer periods of time after ischemic stroke [5]. In
addition, emerging evidence suggests that angiogenesis
can reduce rodent cerebral infarction volumes and
improve neurological function [6–8].
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Throughout the process of angiogenesis, the VEGF/
VEGFR-2 and Ang-1/Tie-2 systems participate in vessel
formation and maturation. A previous study showed that
the VEGF and Ang-1 systems can be co-regulated by
Sonic hedgehog (Shh) signaling in the setting of ische-
mic injury [9]. Shh is a representative morphogen in-
volved in neural development and vessel formation
during embryogenesis [10, 11]. Shh also mediates angio-
genesis during postnatal life in the setting of pathological
conditions [12–14], a subject that has been widely stud-
ied. Shh can induce robust angiogenesis by regulating
VEGF and Ang-1 expression in interstitial mesenchymal
cells [15], and a recent study reported that Shh can
reduce brain infarct volumes and enhance post-ischemic
angiogenesis in MCAO models [16]. Moreover, Shh
pathway inhibition results in decreased VEGF, Ang-1
and CD31 expression in adult mouse hearts [17].
Panaxatriol saponins (PTS), an extract from the trad-
itional Chinese herb Panax notoginseng, is a monomer
compound that is mainly composed of ginsenoside Rg1,
notoginsenoside R1, and ginsenoside Re. PTS has been
used to treat ischemic stroke for many years in China.
However, the mechanism underlying the effects of PTS
remains unclear. Clinical research confirmed that PTS
combined with low dose of aspirin can significantly
ameliorate neurological deficit and activities of daily liv-
ing in patients with light and moderate ischemic stroke
[18]. A previous study showed that PTS protects against
the effects of cerebral ischemia by reducing cerebral
edema and up-regulating heat shock protein70 (HSP70)
expression [19]. A recent study found that PTS can at-
tenuate oxygen-glucose-induced injury in PC12 cells via
PI3K/AKT signaling pathway and Nrf2 signaling pathway
activation [20]. Meanwhile, PTS provided neuroprotec-
tion against dopaminergic neurons loss in 1-methy-4-
phenyl-1,2,3,6-tetrahypdropyridine(MPTP) mouse model
through increasing thioredoxin-1(Trx-1) expression and
inhibiting mitochondria-mediated apoptosis [21]. Fur-
thermore, the main ingredients of PTS, ginsenoside Rg1,
notoginsenoside R1, and ginsenoside Re, are believed to
exert pro-angiogenic effects in human umbilical vein
endothelial cells (HUVECs) and zebrafish chemical-
induced blood vessel loss models [22]. In the current
study, we investigated whether PTS can promote angio-




All animal protocols were approved by the Experimental
Animal Administration Committee of Nanjing University.
Amounting to 210 male Sprague-Dawley rats (250–300 g)
were provided by the Animal Center of Nanjing Drum
Tower Hospital. The rats were individually caged under
specific pathogen-free (SPF) conditions and 12-h light-
dark cycles. They were allowed free access to water and
standard rodent food. All operations were performed
under anesthesia induced by 10% chloral hydrate
(350 mg/kg) to minimize suffering during the study.
Transient middle cerebral artery occlusion (tMCAO) in rats
and drug treatment
The MCAO model was induced as described in a previ-
ous study [23]. Focal ischemic infarction was produced
in the right middle cerebral artery territory. Briefly, a 4-0
surgical nylon suture with a heat-rounded tip was
inserted into the lumen of the internal carotid artery
from the external carotid artery to block the origin of
the right MCA (middle cerebral artery). After 2 h of
ischemia, the filament was withdrawn to allow reperfu-
sion. Heart rate and blood pressure were monitored
during surgery. Sham-operated rats were subjected to
the same procedure without middle cerebral artery
occlusion. PTS was obtained from Huasun Group Co.,
LTD (Sichuan, China). The ginsenoside Rg1, notoginse-
noside R1, and ginsenoside Re are the main components
of PTS with the concentrations of 50, 11 and 6% re-
spectively, as shown in Additional file 1: Figure S1. In a
previous study, different doses of PTS (25, 50 and
100 mg/kg/day) were used, triphenyltetrazolium chloride
(TTC) staining and Longa scores showed that the dose
of 50 mg/kg/day significantly reduced rats infarct vol-
umes and improved neurological deficit scores, but there
is no different between 100 mg/kg/day and 50 mg/kg/
day, as shown in Additional file 2: Figure S2. Thus, the
PTS diluted with saline water into 0.5%, and 50 mg/kg/
day PTS was used in this study.
The rats were randomized divided into the following
three groups: (1) the Sham group: sham-operated rats
i.p. injected with an equal volume of sterile saline; (2)
the vehicle group: MCAO rats i.p. injected with an equal
volume of sterile saline after sugery and once daily; and
(3) the PTS treatment group: MCAO rats i.p. injected
with PTS after sugery and once daily, the drug or saline
first administrated time was at 2 h latter after sugery.
Rats in each group were sacrificed at 1, 3, 7, and 14 days
after surgery for subsequent studies. To label proliferat-
ing cells, we intraperitoneally injected bromodeoxyuri-
dine (Brdu, 50 mg/kg, sigma) within the first 24 h after
surgery and once daily thereafter for 14 days. To explore
the mechanism underlying PTS-induced angiogenesis,
cyclopamine, a specific Shh pathway inhibitor, was dis-
solved in 2-hydroxypropyl-β-cyclodextrin (HPβCD) solu-
tion (1 mg/ml cyclopamine dissolved in 45% HPβCD).
The rats were treated with cyclopamine (10 mg/kg) [24]
via i.p. injections within the first 24 h after surgery and
once daily for 7 consecutive days.
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Neurological functional assessments
Neurological functional evaluations were performed at
6 h, 1, 3, 7 and 14 days after reperfusion, and the evalua-
tors were blinded to the experimental conditions. Neuro-
logical function was assessed using the following modified
Longa five-point scale scoring system: 0: no neurological
deficits; 1: left forelimb flexion; 2: spontaneous left circ-
ling; 3: falls to the left; and 4: no spontaneous movement
or loss of consciousness. Rats with scores of 1–3 points
were used in this study.
Measurement of brain infarct volumes
At 1, 3 and 7 days after surgery, the rats were sacrificed
under anesthesia. Their brains were sliced into 2.0 mm
sections and immersed in 2% TTC (Sigma, USA) for
30 min and then fixed in 4% paraformaldehyde over-
night at 4 °C. Normal brain tissue appeared red, and
infarcted tissue appeared in pale gray. The slices were
photographed, and infarct volumes were calculated using
Image-Pro Plus 6.0 software (Media Cybernetics) by a
blinded investigator. To determine if cerebral edema was
present, the infarct volumes were presented as percent-
ages of the volumes of the contralateral hemispheres. At
14 days after surgery, the rats were anesthetized and per-
fused with 0.9% saline, and their brains were fixed in 4%
paraformaldehyde before being cut into 30 μm coronal
sections. One of every 7 consecutive slices was randomly
selected for neuronal staining. Infarcted regions were
defined as those with absent neuronal staining.
Micro-PET
Micro-PET information was recorded after cerebral
reperfusion at 1 and 14 days after surgery by a blinded
investigator. Before PET, the rats were deprived of food
for 12 h to enhance brain FDG uptake. FDG (1.0–
1.5 mCi/kg) was injected via the tail vein under
anesthesia. The injection time, FDG dose, residual dose
measurement, and measuring residual time were re-
corded. FDG was allowed to circulate in the blood for
60 min, and then the animals were fixed on the special
scanning bed for a 10 min micro-PET scan. Images
obtained using a small-animal PET scanner (Inveon,
Germany SIMENS company), and the OSEM 3D
format was used to acquire regions of interest.
Real-time PCR
As described previously [25], total RNA was isolated at
1, 3, 7 and 14 days after MCAO using Trizol reagent
(Invitrogen, USA) and then reversed transcribed to
cDNA using a PrimeScript RT Reagent Kit (Takara,
Dalian, China). Quantitative PCR was performed by an
ABI StepOnePlus Real-time PCR System (Applied
Biosystems, USA) with fluorescent dye (SYBR Green I,
Takara). Protocol of the real-time PCR was conducted as
follows: holding stage at 95 °C for 30 s, followed by 95 °
C for 5 s, 60 °C for 34 s, 40 cycles. To obtain a melting
curve as follows: holding at 95 °C for 15 s, cooling to
60 °C for 1 min, and then heating slowly at 0.3 °C/s until
95 °C for 15 s. The primer sequences were as follows:
VEGF: F: CGA CAG AAG GGG AGC AGA AAG and
R: GCA CTC CAG GGC TTC ATC ATT; Ang-1: F:
GTC ACT GCA CAA AAG GGA CA and R: GGC TTA
CAA GGA TGG CGT TA; VEGFR-2: F: TAGCACGAC
AGAGACTGTGAGG and R: TGAGGTGAGAGAGA
TGGGTAGG; Tie-2: F: TGCCACCATCACTCAATACC
and R: AAACGCCAATAGCACGGTGA; CD31: F: TTT
CGCTGCCAAGCTGGCGT and R: CCACCTGCACGC
TGCACTTGAT; α-SMA: F: TGGCCACTGCTGCTTC
CTCTTCTT and R: GGGGCCAGCTTCGTCATACTC
CT; and GAPDH: F: CTC TAA GGC TGT GGG CAA
GGT CAT and R: GAG ATC CAC CAC CCT GTT
GCT GTA. For GAPDH constantly express in the brain,
so we select it as comparator in our experiment. The
relative mRNA expression were normalized to GAPDH
levels and analyzed using the 2−ΔΔCT method.
Western blotting
The rats were euthanized and decapitated, and their
ischemic ipsilateral cortices were rapidly dissected on ice
and stored at −80 °C until needed. The samples were
then taken from the freezer and sonicated in RIPA buffer
(Beyotime Institute of Biotechnology, China) containing
phosphatase and protease inhibitor cocktails. A BCA Kit
(Beyotime Biotechnology) was then used to determine
the protein concentrations. Equal amounts of sample
were separated by SDS-PAGE and transferred onto
PVDF membranes, which were blocked in 5% non-fat
dry milk at room temperature for 1 h. The membranes
were then incubated overnight at 4 °C with primary anti-
bodies against VEGF (1:1000 Bioworld Technology,
USA), Ang-1 (1:1000 Bioworld Technology, USA), Shh
(1:250 Life Technology, USA), Patched-1 (1:1000 Abcam,
UK), Smoothened (1:1000 Abcam, UK) and Beta-actin
(1:5000 Bioworld, USA). The next day, the membranes
were incubated with the appropriate HRP-conjugated
secondary antibodies for 2 h at room temperature.
Immunoreactive bands were visualized with chemilu-
minescence reagents that were provided with an ECL kit
(Bioworld, USA). Blot intensity was detected using
Image J software.
Immunofluorescence staining
The animals were sacrificed via cardiac perfusion with
0.9% saline, and their brains were fixed in 4% parafor-
maldehyde before being cut into 20 μm coronal sections.
Double-immunofluorescence staining was employed in
order to specifically for identifying endothelial cells (EC)
and pericytes colocalized vessels in ischemia boundary
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zones (IBZs). CD31 is an endothelial cell marker, and α-
smooth muscle actin (α-SMA) is a pericyte marker. For
CD31 and α-SMA-positive vessel density quantification,
the brain slices were incubated with anti-CD31 (1:200,
Abcam, USA) and anti-α-SMA (1:50, Santa Cruz, CA,
USA) antibodies overnight at 4 °C. After being washed
with phosphate buffer solution (PBS), the sections were
incubated with the appropriate secondary antibodies for
2 h in the dark at room temperature. Cell nuclei were
stained with DAPI. Five slides of each brain were se-
lected, and each slide contained three to four fields of
view of the IBZ (ischemic boundary zone). To analyze
EC proliferation, we calculated the percentage of Brdu-
positive endothelial cells in the IBZ. The brain sections
were imaged using an Olympus microscope with a BX51
digital camera (Olympus, Japan), and the images were
quantified with IPP 6.0 software. All evaluations were
performed by a blinded investigator.
Statistical analysis
All data are presented as the mean ± standard error (SE)
and were analyzed using SPSS 16.0 statistical analysis
software (SPSS, Chicago, IL, USA). Student’s t-test was
used to assess the differences between two groups.
Differences among multiple groups were analyzed via
one-way analysis of variance (ANOVA). P < 0.05 was
considered statistically significant. All evaluations were
performed in a blinded manner.
Results
PTS attenuates ischemic brain injury in rats
To explore the effects of PTS on ischemic brain injury,
we assessed infarct volumes and neurological deficit
scores. TTC staining indicated that PTS administration
significantly reduced infarct volumes in treated rats
compared to vehicle rats at 3 and 7 days after surgery
(Fig. 1a and c). Immunofluorescence staining showed
that neuron loss was significantly decreased in PTS rats
at 14 days after cerebral ischemia-reperfusion (Fig. 1b).
Neurological deficit score results showed that PTS can
improve neurological function at 3 days after surgery
and that this effect lasts for 14 days (Fig. 1d). These re-
sults confirmed that PTS exerts neuroprotective effects
in the setting of experimental ischemic stroke-induced
brain injury.
PTS enhances cerebral perfusion in ischemic brain tissue
PET with 18F-FDG is a powerful and noninvasive tool
for assessing the effects of cerebrovascular disease ther-
apy [26]. Micro-PET/CT was performed to determine
Fig. 1 PTS protects against ischemia-induced brain injury. PTS can reduce brain infarct volumes and improve neurological deficit scores after
MCAO in rats. a TTC staining showing infarct volumes at 3 and 7 days after surgery. Normal brain tissue appears red, and infarcted tissue appears
pale gray. b Neuron immunofluorescence staining (green) showing neuronal loss at 14 days after surgery, c Quantitative analysis of brain infarct
volumes in vehicle- and PTS-treated rats at 1, 3, 7 days after MCAO. *P < 0.05, **P < 0.01 versus Veh group, n = 6 per group. d Neurological deficit
scores in the two groups were assessed by the Longa scale scoring system at 6 h, 1, 3, 7, and 14 days after reperfusion.*P < 0.05 versus Veh group,
n = 10 per group
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whether PTS can improve cerebral blood flow in rats
after MCAO. The results showed that 18F-PDG uptake
was significantly decreased in ischemic brain tissue at
1 day after MCAO (Fig. 2a and b). Interestingly, at
14 days after surgery, 18F-PDG uptake was significantly
higher in the PTS group than in the vehicle group
(Fig. 2a and b). These results show that PTS can en-
hance cerebral perfusion in the ischemic boundary zones
of experimental stroke rats.
PTS promotes angiogenesis factor expression in ischemic
cortical tissue
The relative levels of VEGF, Ang-1, VEGFR-2, Tie-2,
CD31 and α-SMA mRNA expression in ischemic lateral
cortical tissue were measured using real-time PCR. The
results showed that VEGF and Ang-1 expression was
increased after MCAO and that PTS can significantly
increase VEGF and Ang-1 mRNA expression at 3, 7 and
14 days after surgery in treated rats compared to vehicle
rats (Fig. 3a and b). These results were consistent with
those of a prior report [27]. VEGFR-2 and Tie-2 expres-
sion was also increased at different time points after
surgery (Fig. 3c and d). The mRNA expression levels
both receptors peaked at 7 days before decreasing at
14 days after surgery. PTS administration significantly
increased their expression at 3, 7 and 14 days after
surgery. PTS also up-regulated the levels of CD31 and
α-SMA mRNA expression in treated rats compared to
vehicle rats beginning at 3 days after surgery. These
increases persisted until 14 days after cerebral ischemia-
reperfusion (Fig. 3e and f). In addition, the levels of
VEGF and Ang-1 protein expression were also detected
by western blotting. VEGF expression tended to increase
after MCAO, peaking at 7 days and then decreasing at
14 days after surgery. These results were consistent with
those of a previous study [23], Ang-1 protein expres-
sion tended to increase after MCAO, and PTS signifi-
cantly increased both VEGF and Ang-1 protein
expression in ischemic lateral cortical tissue in treated
rats compared with vehicle rats at 3, 7 and 14 days after
surgery (Fig. 3g, h, i).
PTS increases angiogenesis in ischemic cortical tissue
Accumulating evidence indicates that angiogenesis plays
an important role in ischemic stroke-induced brain in-
jury repair and long-term functional recovery [3] A pre-
vious study reported that capillary sprouting and vessel
growth continue for at least 3 weeks after ischemic in-
jury in ischemic boundary zones [28]. In this study, to
evaluate the effect of PTS on ischemic brain microcircu-
lation, we examined the expression of the endothelial
cell marker CD31 and the pericyte marker α-SMA in is-
chemic ipsilateral cortical tissue via immunostaining at
different time points. The results showed that ischemia
substantially induces angiogenesis in brain penumbra in
rats and that vessel density peaks at 7 days before de-
creasing at 14 days after surgery. CD31 and α-SMA
colocalizationed vessels density was significantly higher
in the PTS group than in the vehicle group at 7 and
14 days after surgery (Fig. 4a-b). It is known that the
processes of post-stroke neurogenesis and angiogenesis
are linked together [29]; therefore, PTS may improve
cerebral perfusion and promote neural functional recov-
ery by promoting angiogenesis.
PTS promotes endothelial cell proliferation after MCAO
To verify the effects of PTS on endothelial cell prolifera-
tion after MCAO, we intraperitoneally injected rats with
Fig. 2 PTS enhances cerebral perfusion in stroke rats. a 18F-FDG micro-PET image showing brain perfusion in the different groups at 1 and 14 days
after MCAO. b Quantitative analysis of 18F-FDG uptake in the different groups at 1 and 14 days after cerebral reperfusion. Data are presented as
the mean ± SEM, #P < 0.05 versus Sham group; *P < 0.05 versus Veh group, n = 6 per group
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Fig. 3 PTS promotes angiogenesis factor expression in ischemic lateral cortical tissue. PTS promotes angiogenesis factor expression in ischemic lateral
cortical tissue at different time points. The mRNA levels of VEGF (a), Ang-1 (b), VEGFR2 (c), Tie-2 (d), CD31 (e), and α-SMA (f) were determined by
real-time PCR at 1, 3, 7, and 14 days after MCAO. Data are presented as the mean ± SEM, #P < 0.05 versus Sham group; *P < 0.05, **P < 0.01 versus Veh
group. n = 6 per group. g The protein levels of VEGF and Ang-1 were measured by western blotting. (h-i) Quantitative analysis of VEGF and Ang-1
expression. #P < 0.05 versus Sham group; *P < 0.05 versus Veh group. n = 6 per group
Fig. 4 PTS increases microvascular density in ischemic cortical tissue. PTS can increase CD31 and α-SMA colocalization in ischemia boundary zones.
a CD31 (red) and α-SMA (green) double-immunostaining in the ischemia boundary zone (IBZ) at 7 and 14 days after surgery. Scale bar = 50 μm.
b Quantitative analysis of the microvessels in the IBZ. Data are presented as the mean ± SEM. #P < 0.05 versus Sham group; *P < 0.05 versus Veh group.
n = 6 per group. c The typical detected areas of CD31 and α-SMA colocalization in boxed zones of brain slices
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Brdu, a thymidine analog that is incorporated into the
DNA of dividing cells during S-phase. CD31 and Brdu
double-staining was used to mark newborn endothelial
cells, as shown in Fig. 5a and b. EC proliferation was
observed in the IBZ after surgery, and PTS apparently
increased the numbers of CD31- and Brdu-double-
stained cells in the treated group compared with the
vehicle group at 14 days after surgery, confirming that
PTS promotes EC proliferation after ischemic stroke.
PTS modulates pro-angiogenic factor expression by
activating the Shh pathway
To elucidate the mechanism underlying PTS-induced
increases in angiogenesis, Shh pathway activity was de-
tected by western blotting. The expression of Shh and
two transmembrane receptors, Ptch-1 (Patched-1), Smo
(Smoothened), was detected in the study. As shown in
Fig. 6a and b, PTS up-regulated Shh activity and Ptch-1
and Smo expression in the treated group compared with
the Sham group at 7 days after cerebral reperfusion. To
determine whether PTS increases VEGF and Ang-1 ex-
pression via the Shh pathway, PTS was administered
with and without the specific Shh pathway inhibitor CY
(cyclopamine). As shown in Fig. 6c and d, the levels of
VEGF and Ang-1 protein expression were dramatically
decreased in cyclopamine-treated rats. These data indi-
cate that PTS at least partially regulates VEGF and Ang-
1 expression via the Shh pathway.
Discussion
In the current study, we demonstrated that PTS admin-
istration can reduce brain infarction volumes and im-
prove neurological deficits in a rat focal ischemic injury
model. Furthermore, we showed that PTS can improve
cerebral blood perfusion and that the mechanism under-
lying these effects may be associated with Shh pathway
activation and VEGF and Ang-1 expression regulation.
Ischemic stroke, which is induced by cerebral artery
occlusion, dramatically decreases local cerebral blood
flow, causing cell death, brain atrophy, and functional
deficits. Restoration of local blood perfusion in ischemic
brain tissue plays a key role in tissue repair and func-
tional recovery [30]. The early response facilitates cere-
bral blood flow recovery through collateral circulation
and anastomotic vessel activation, and the long-term
response involves angiogenesis [31]. Angiogenesis is de-
fined as the growth of new vessels from pre-existing
blood vessels, which occurs in the ischemic boundary
zones of brain infarct regions. Mounting evidence
indicates that angiogenesis is involved in neurological
functional recovery and can improve cerebral microcir-
culation perfusion and reduce infarct volumes [23, 29].
In our study, PTS administration significantly improved
rat neurological deficit scores, reduced infarct volumes
at 3, 7 and 14 days after MCAO, enhanced 18F-PDG up-
take in ischemic brain tissue, and increased cerebral per-
fusion after surgery. These results confirmed that PTS
exerts protective effects on ischemic brain injury.
Fig. 5 PTS enhances vascular endothelial cell proliferation in ischemic cortical tissue. PTS can increase the number of CD31- and Brdu-double-
immunostained cells in ischemic lateral cortical tissue after MCAO. a CD31 (red) and Brdu (green) double-immunostaining in the ischemia boundary
zone (IBZ) at 14 days after surgery. Scale bar = 20 μm b Quantitative analysis of colocalized endothelial cells in the IBZ. #P < 0.05 versus Sham group;
*P < 0.05 versus Veh group. n = 6 per group
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Angiogenesis is a multi-step biological process involv-
ing the proliferation and sprouting of endothelial cells,
the formation of tube-like vascular structures, and the
branching and anastomosis of new vessels. Many cyto-
kines take part in this complicated process, such as
VEGF, Ang-1, HIF-1, bFGF, and EPO. VEGF and Ang-1
play the most prominent roles in angiogenesis after is-
chemic injury. VEGF is probably the most important
angiogenesis inducer during the early stages of recovery
from ischemic stroke. VEGF promotes angiogenesis by
up-regulating VEGFR-2 expression [32]. VEGF binds to
VEGFR-2 and then triggers EC mitotic and migratory
processes to facilitate tube formation [33]; however, this
process may increase microvessel leakage and induce
brain edema. Ang-1 promotes angiogenesis and new
vessel remodeling, and also acts as an anti-permeability
factor, Ang-1 binds to its specific receptor Tie-2 and
recruits mural cells to wrap around endothelial cells,
thereby ensuring the eventual maturation and stabilization
of new blood vessels [34]. Therefore, VEGF and Ang-1
exert synergistic effects on angiogenesis after stroke [35].
A previous study showed that ECs begin mitosis as early
as 1 day after mouse cerebral reperfusion after 30 min of
MCAO and that the number of vessels begins to
significantly increase on the third day before peaking at
7 days after stroke. The levels of VEGF and Ang-1 were
increased, too [28]. In addition, hydrogen sulfide increases
VEGF and Ang-1 expression in ischemic brain tissue at
7 days after MCAO, as well as the numbers of Brdu- and
CD31-double-positive cells in the ipsilateral hemisphere
[1]. In this study, CD31 and α-SMA colocalization was
significantly higher in the PTS group than in the vehicle
group at 7 and 14 days after MCAO, confirming that PTS
significantly promotes angiogenesis and enhances neovas-
cular integrity. We also examined VEGF/VEGFR2 and
Ang-1/Tie-2 expression in ischemic brain cortical tissue.
The results showed that VEGF and VEGFR2 mRNA levels
were increased after PTS injection at different time points,
findings that were consistent with those regarding Ang-1
and Tie-2 expression. In addition, western blotting con-
firmed that the levels of VEGF and Ang-1 protein expres-
sion were also significantly increased in the PTS group at
different time points after surgery.
The study confirmed that PTS can effectively promote
angiogenesis after ischemic stroke in rats, but the mech-
anism underlying the effects of PTS is unknown. Previous
studies have reported that VEGF can be regulated by mul-
tiple signaling pathways, such as the PI3K/AKT [36],
Fig. 6 PTS modulates VEGF and Ang-1 expression through Shh pathway activation. a Shh pathway component levels were measured by western
blotting at 7 days after surgery. b Quantitative analysis of Shh, Ptch-1 and Smo expression. #P < 0.05 versus Sham group; *P < 0.05 versus Veh
group. n = 6 per group. c The protein levels of VEGF and Ang-1 were measured by western blotting in the different groups at 7 days after surgery.
d Quantitative analysis of VEGF and Ang-1 expression. *P < 0.05 versus Veh group. ##P < 0.01 versus PTS group; n = 6 per group
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Apelin-APJ [37], and DLL4/Notch signaling pathways
[38]. However, few studies have examined the mechanism
underlying upstream Ang-1 regulation. A recent study
showed that the Shh signaling pathway can co-regulate
two angiogenic cytokine families, namely, those to which
VEGF and Ang-1 and Ang-2 belong [15]. The Shh signal-
ing pathway is an evolutionarily conserved developmental
signaling cascade that regulates multiple biologic pro-
cesses, such as embryonic development, injury repair, and
angiogenesis [39]. Shh transmits its signal by binding to
the plasma membrane receptor Ptch-1, leading to Ptch-
1 internalization and degradation, Smo de-repression,
and downstream transcription factor activation [40]. In
addition, Shh exerts protective effects in several animal
ischemia/reperfusion models, including cerebral and
myocardial infarction and hind-limb ischemia models
[41, 42]. A previous study showed that endogenous Shh
expression is up-regulated in hippocampal neurons
after focal ischemia and that cyclopamine, an Shh path-
way inhibitor, can suppress post-ischemic sub-granular
neural progenitor cell proliferation [43]. Shh can increase
VEGF, Ang-1, and Ang-2 expression in astrocytes after
oxygen–glucose deprivation (OGD). Moreover, a previous
study showed that inhibiting the Shh signaling pathway
with 5EI decreased VEGF, Ang-1, and Ang-2 expression
[44]. The current study illustrated that PTS up-regulated
Shh, Ptch-1 and Smo expression after reperfusion and also
increased the levels of VEGF and Ang-1 protein expres-
sion. In addition, the Shh pathway could be inhibited by
cyclopamine, and cyclopamine-treated rats exhibited
dramatically decreased VEGF and Ang-1 protein expres-
sion. These data demonstrate that PTS activates the Shh
pathway after ischemia-reperfusion injury, which may
contribute to its neuroprotective effects.
Conclusion
In summary, our study confirmed that PTS enhances
cerebral blood flow, promotes cerebral angiogenesis and
modulates VEGF and Ang-1 expression. The molecular
mechanism underlying the effects of PTS may be associ-
ated with Shh pathway activation. PTS may be a promis-
ing drug for ischemic stroke treatment.
Additional files
Additional file 1: Figure S1. HPLC chromatogram of PTS. The
ginsenoside Rg1, notoginsenoside R1, and ginsenoside Re are the main
components of PTS with the the concentrations of ≥ 50%, ≥ 11% and ≥
6% respectively. (DOC 50 kb)
Additional file 2: Figure S2. In a previous study, different doses of PTS
(25, 50 and 100 mg/kg/day) were used after MCAO rats. (a) Quantitative
analysis of brain infarct volumes in four groups at 3 d after MCAO. *P<0.05,
versus Veh group, n = 10 per group. (b) Neurological deficit scores in the
four groups were assessed by the Longa scale scoring system at 6 h, 1 d, 3 d
after reperfusion.*P<0.05 versus Veh group, n = 10 per group. (TIF 318 kb)
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